Grabar Law Office is investigating claims on behalf of Charles River Laboratories International, Inc. (NYSE: CRL) shareholders. The investigation concerns whether certain officers of Charles River have breached their fiduciary duties owed to the company.

A federal securities class action lawsuit has been filed against Charles River Laboratories International, Inc. The lawsuit alleges Charles River, via certain officers and directors, made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including: (1) that Charles River had engaged in illegal activity with respect to its importation of non-human primates for research; (2) that, as a result, Charles River was at a heightened risk of criminal and regulatory investigation by the U.S. Department of Justice; (3) that, as a result, Charles River would be forced to suspend shipments of primates from Cambodia; and (4) that, as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis when made.

Current Charles River shareholders who have continuously held Charles River shares since on or before May 5, 2020, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.

If you would like to learn more about this matter, you are encouraged to contact us at jgrabar@grabarlaw.com, or call Joshua Grabar at 267-507-6085.